Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 11/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471683 | 0.89 | CHRM2 (0.36) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL20599068 | 0.86 | NOTUM (0.46) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21471714 | 0.86 | CHRM2 (0.38) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21471675 | 0.85 | ALDH1A1 (0.47) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21457978 | 0.83 | PIK3CA (0.38) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL20619490 | 0.83 | ALDH1A1 (0.50) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21471717 | 0.82 | MAPK14 (0.41) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21474620 | 0.82 | MAPK14 (0.41) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL20622402 | 0.80 | HPGD (0.42) | KDM4EALDH1A1GAAL3MBTL1CHRM2 | |
| SCHEMBL21471792 | 0.79 | CHRM2 (0.36) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | KDM4E 1288/4885ALDH1A1 701/4885GAA 587/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | KDM4E 1288/4885ALDH1A1 701/4885GAA 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.